US · RMD · MEDICAL - DEVICES
ResMed Inc. (RMD) intrinsic value and stock valuation
$235.63as of 2026-11-21 · Mkt cap 32.5B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
ResMed Inc. DCF and intrinsic value
InvestorsCraft values RMD with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from RMD’s statements →
ResMed Inc. Graham Number
Graham Number: $93.48d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Cardinal Health, Inc. (CAH) $272.81
- Becton, Dickinson and Company (BDX) $212.78
- Haleon plc (HLN) $9.07
- Humana Inc. (HUM) $389.91
- Agilent Technologies, Inc. (A) $170.38
- IQVIA Holdings Inc. (IQV) $245.82
- Alcon Inc. (ALC) $74.31
- GE HealthCare Technologies Inc. (GEHC) $80.64
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | — | $5.15B | $4.69B | $4.22B | $3.58B |
| Operating income | — | $1.69B | $1.32B | $1.13B | $1B |
| Net income | — | $1.4B | $1.02B | $897.6M | $779.4M |
| EPSd | — | $9.51M | $6.92M | $6.09M | $5.3M |
| Operating cash flow | $1.81B | $1.75B | $1.4B | $693.3M | $351.2M |
| Capital expenditure | -$-156.28M | -$-89.86M | -$-114.86M | -$-134M | -$-156.04M |
| Free cash flow | $1.65B | $1.66B | $1.29B | $559.3M | $195.1M |
| Total assets | — | $8.17B | $6.87B | $6.75B | $5.1B |
| Total debt | — | $851.8M | $873.9M | $1.58B | $917.6M |
| Net debt | — | -$-357.64M | $635.6M | $1.35B | $643.8M |
| Total equity | — | $5.97B | $4.86B | $4.13B | $3.36B |
| Cash and short-term investments | — | $1.21B | $238.4M | $227.9M | $273.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $5.15B | $4.69B | $4.22B | $3.58B | $3.2B |
| Cost of revenue | $2.09B | $2.03B | $1.87B | $1.55B | $1.36B |
| Gross profit | $3.05B | $2.66B | $2.36B | $2.02B | $1.84B |
| Research and development expenses | $331.3M | $307.5M | $287.6M | $253.6M | $225.3M |
| Selling, general and administrative expenses | $991M | $917.1M | $874M | $739.4M | $670.4M |
| Other expenses | $47.3M | $110.8M | $62.2M | $31.1M | $39.8M |
| Operating expenses | $1.37B | $1.34B | $1.22B | $1.02B | $935.4M |
| Cost and expenses | $3.46B | $3.37B | $3.09B | $2.58B | $2.29B |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $360K |
| Interest expense | $12.6M | $45.7M | $47.4M | $22.3M | $24M |
| Depreciation and amortization | $235.8M | $216.2M | $196.5M | $193.8M | $191.5M |
| Ebitda | $1.91B | $1.53B | $1.36B | $1.18B | $1.1B |
| Operating income | $1.69B | $1.32B | $1.13B | $1B | $903.7M |
| Total other income/expenses, net | -$-7.8M | -$-55.09M | -$-30.21M | -$-39.8M | -$-20.02M |
| Income before tax | $1.68B | $1.26B | $1.1B | $960.5M | $883.7M |
| Income tax expense | $276.8M | $243.9M | $204.1M | $181.1M | $409.2M |
| Net income | $1.4B | $1.02B | $897.6M | $779.4M | $474.5M |
| Weighted average shares outstanding | $146.7M | $147M | $146.8M | $146.1M | $145.3M |
| Weighted average diluted shares outstanding | $147.3M | $147.6M | $147.5M | $147M | $146.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.21B | $238.4M | $227.9M | $273.7M | $295.3M |
| Net receivables | $990.7M | $837.3M | $704.9M | $576M | $625.2M |
| Inventory | $927.7M | $822.3M | $998M | $743.9M | $457M |
| Total current assets | $3.51B | $2.36B | $2.37B | $1.93B | $1.57B |
| Property, plant and equipment, net | $718.3M | $699.2M | $665.8M | $630.5M | $592.1M |
| Goodwill and intangible assets | $3.51B | $3.33B | $3.32B | $2.28B | $2.32B |
| Long-term investments | $85M | $169.8M | $156.9M | $67.2M | $75.5M |
| Total non-current assets | $4.67B | $4.51B | $4.38B | $3.16B | $3.15B |
| Total assets | $8.17B | $6.87B | $6.75B | $5.1B | $4.73B |
| Accounts payable | $278.2M | $237.7M | $150.8M | $159.3M | $138M |
| Short-term debt | $40.4M | $35.2M | $31.8M | $31.8M | $35.6M |
| Deferred revenue | $166M | $152.6M | $138.1M | $108.7M | $109.6M |
| Total current liabilities | $1.02B | $910.7M | $758.5M | $689.3M | $911.8M |
| Long-term debt | $811.4M | $838.8M | $1.55B | $885.8M | $758.1M |
| Deferred revenue, non-current | $156.8M | $137.3M | $119.2M | $95.5M | $91.5M |
| Total non-current liabilities | $1.19B | $1.1B | $1.86B | $1.05B | $930.7M |
| Capital lease obligations | $183.5M | $166.7M | $138.8M | $142.3M | $138.4M |
| Total liabilities | $2.21B | $2.01B | $2.62B | $1.74B | $1.84B |
| Common stock | $760K | $590K | $590K | $590K | $580K |
| Retained earnings | $6.08B | $4.99B | $4.25B | $3.61B | $3.08B |
| Accumulated other comprehensive income (loss) | -$-74.7M | -$-251.53M | -$-272.53M | -$-312.75M | -$-193.49M |
| Total equity | $5.97B | $4.86B | $4.13B | $3.36B | $2.89B |
| Total investments | $85M | $169.8M | $156.9M | $67.2M | $75.5M |
| Total debt | $851.8M | $873.9M | $1.58B | $917.6M | $793.7M |
| Net debt | -$-357.64M | $635.6M | $1.35B | $643.8M | $498.4M |
Cash flow statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Net income | $1.52B | $1.4B | $1.02B | $897.6M | $779.4M |
| Depreciation and amortization | $244.2M | $235.8M | $216.2M | $197.6M | $193.8M |
| Stock-based compensation | $104.4M | $91.7M | $80.2M | $71.1M | $65.3M |
| Change in working capital | -$-74.24M | $16.7M | $44.8M | -$-462.13M | -$-708.08M |
| Accounts receivable | -$-96.78M | -$-76.68M | -$-134.28M | -$-106.51M | $19.4M |
| Inventory | -$-9.92M | -$-80.17M | $172.2M | -$-248.83M | -$-311.68M |
| Accounts payable | $172.7M | $91M | $0.00 | $31.3M | -$-247.63M |
| Net cash provided by operating activities | $1.81B | $1.75B | $1.4B | $693.3M | $351.2M |
| Investments in property, plant and equipment | -$-156.28M | -$-89.86M | -$-99.46M | -$-134M | -$-156.04M |
| Acquisitions, net | -$-350.72M | -$-139.25M | -$-133.46M | -$-1.01B | -$-42.78M |
| Net cash used for investing activities | -$-545.2M | -$-200.04M | -$-269.78M | -$-1.16B | -$-229.92M |
| Common stock issued | $74.5M | $74.4M | $53.1M | $49.1M | $47.4M |
| Common stock repurchased | -$-700.04M | -$-300.02M | -$-150.01M | $0.00 | $0.00 |
| Dividends paid | -$-349.66M | -$-310.88M | -$-282.32M | -$-258.28M | -$-245.34M |
| Net cash used for financing activities | -$-1.01B | -$-606.25M | -$-1.12B | $422.9M | -$-128.36M |
| Net change in cash | $259.8M | $971.1M | $10.5M | -$-45.82M | -$-21.57M |
| Cash at end of period | $1.47B | $1.21B | $238.4M | $227.9M | $273.7M |
| Operating cash flow | $1.81B | $1.75B | $1.4B | $693.3M | $351.2M |
| Capital expenditure | -$-156.28M | -$-89.86M | -$-114.86M | -$-134M | -$-156.04M |
| Free cash flow | $1.65B | $1.66B | $1.29B | $559.3M | $195.1M |
Line items
Line items
Line items
About ResMed Inc.
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
- CEO
- Michael J. Farrell
- Employees
- 10.6K
- Beta
- 0.78
Included in
Explore
Frequently asked questions
What is the intrinsic value of ResMed Inc. (RMD)?
ResMed Inc. (RMD) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is RMD undervalued?
RMD trades at a price of $235.63 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.